Norihisa Shigemura

Prof. Norihisa Shigemura

Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA 19140, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in JACC
Verified
Journal Article
Closed access
NNNoritsugu Naito
Noritsugu Naito
KCKeith Cook
Keith Cook
YTYoshiya Toyoda
Yoshiya Toyoda
Norihisa ShigemuraNorihisa Shigemura
Norihisa Shigemura

1 January 2017 in World Journal of Transplantation
Verified
Journal Article
Open access
MEMichael Eberlein
Michael Eberlein
Robert M. ReedRobert M. Reed
Robert M. Reed
MCMayy Chahla
Mayy Chahla
Servet BölükbasServet Bölükbas
Servet Bölükbas
ABAmy Blevins
Amy Blevins
TDTobias Deuse
Tobias Deuse
To systematically review reports on deceased-donor-lobar lung transplantation (ddLLTx) and uniformly describe size matching using the donor-to-recipient predicted-total lung-capacity (pTLC) ratio. We set out to systematically review reports on ddLLTx and uniformly describe size matching using the donor-to-recipient pTLC ratio and to summarize reported one-year survival data of ddLLTx and conventional-LTx. We searched in PubMed, CINAHL via EBSCO, Cochrane Database of Systematic Reviews via Wiley (CDSR), Database of Abstracts of Reviews of Effects via Wiley (DARE), Cochrane Central Register of Controlled Trials via Wiley (CENTRAL), Scopus (which includes EMBASE abstracts), and Web of Science for original reports on ddLLTx. Nine observational cohort studies reporting on 301 ddLLTx met our inclusion criteria for systematic review of size matching, and eight for describing one-year-survival. The ddLLTx-group was often characterized by high acuity; however there was heterogeneity in transplant indications and pre-operative characteristics between studies. Data to calculate the pTLC ratio was available for 242 ddLLTx (80%). The mean pTLCratio before lobar resection was 1.25 ± 0.3 and the transplanted pTLCratio after lobar resection was 0.76 ± 0.2. One-year survival in the ddLLTx-group ranged from 50%-100%, compared to 72%-88% in the conventional-LTx group. In the largest study ddLLTx (n = 138) was associated with a lower one-year-survival compared to conventional-LTx (n = 539) (65.1% vs 84.1%, P < 0.001). Further investigations of optimal donor-to-recipient size matching parameters for ddLLTx could improve outcomes of this important surgical option.

20 January 2021 in Transplant International
Verified
Journal Article
Closed access
PDF file
OTOlga A. Timofeeva
Olga A. Timofeeva
JCJason Choe
Jason Choe
MAMohamed Alsammak
Mohamed Alsammak
EYEdward J. Yoon
Edward J. Yoon
SGSteven S. Geier
Steven S. Geier
JBJames C. Brown
James C. Brown
Antibody‐Mediated Rejection (AMR) due to donor‐specific antibodies (DSA) is associated with poor outcomes after lung transplantation. Currently there are no guidelines regarding the selection of treatment protocols. We studied how DSA characteristics including titers, C1q, and mean fluorescence intensity (MFI) values in undiluted and diluted sera may predict a response to therapeutic plasma exchange (TPE) and inform patient prognosis after treatment. Among 357 patients consecutively transplanted without detectable pre‐existing DSAs between 01/01/16 and 12/31/18, 10 patients were treated with a standardized protocol of five TPE sessions with IVIG. Based on DSA characteristics after treatment, all patients were divided into three groups as responders, partial responders, and non‐responders. Kaplan‐Meier Survival analyses showed a statistically significant difference in patient survival between those groups (P= 0.0104). Statistical analyses showed that MFI in pre‐TPE 1:16 diluted sera was predictive of a response to standardized protocol (R2=0.9182) and patient survival (P=0.0098). Patients predicted to be non‐responders who underwent treatment with a more aggressive protocol of 8 TPE sessions with IVIG and bortezomib showed improvements in treatment response (P=0.0074) and patient survival (P= 0.0253). Dilutions may guide clinicians as to which patients would be expected to respond to a standards protocol or require more aggressive treatment.

23 October 2020 in Artificial Organs
Verified
Journal Article
Open access
PDF file
JSJustyna Swol
Justyna Swol
Norihisa ShigemuraNorihisa Shigemura
Norihisa Shigemura
SIShingo Ichiba
Shingo Ichiba
USUlrich Steinseifer
Ulrich Steinseifer
MAMasaki Anraku
Masaki Anraku
RLRoberto Lorusso
Roberto Lorusso
Lung transplantation may be a final destination therapy in lung failure, but limited donor organ availability creates a need for alternative management, including artificial lung technology. This invited review discusses ongoing developments and future research pathways for respiratory assist devices and tissue engineering to treat advanced and refractory lung disease. An overview is also given on the aftermath of the coronavirus disease 2019 pandemic and lessons learned as the world comes out of this situation. The first order of business in the future of lung support is solving the problems with existing mechanical devices. Interestingly, challenges identified during the early days of development persist today. These challenges include device‐related infection, bleeding, thrombosis, cost, and patient quality of life. The main approaches of the future directions are to repair, restore, replace, or regenerate the lungs. Engineering improvements to hollow fiber membrane gas exchangers are enabling longer term wearable systems and can be used to bridge lung failure patients to transplantation. Progress in the development of microchannel‐based devices has provided the concept of biomimetic devices that may even enable intracorporeal implantation. Tissue engineering and cell‐based technologies have provided the concept of bioartificial lungs with properties similar to the native organ. Recent progress in artificial lung technologies includes continued advances in both engineering and biology. The final goal is to achieve a truly implantable and durable artificial lung that is applicable to destination therapy.

6 June 2022 in Transplantation
Verified
Journal Article
Closed access
GSGengo Sunagawa
Gengo Sunagawa
HKHiromu Kehara
Hiromu Kehara
CMChirantan Mangukia
Chirantan Mangukia
SBStacey Brann
Stacey Brann
ELEros Leotta
Eros Leotta
Norihisa ShigemuraNorihisa Shigemura
Norihisa Shigemura
Background.: Although double lung transplant is recommended in patients with severe secondary pulmonary hypertension (SPH), our institutional experiences suggest a role for single lung transplant in these patients. Here, we review our experience prioritizing single lung transplant in patients with SPH to minimize their surgical burden. Methods.: We conducted a retrospective review of our lung transplant database to identify patients with SPH who underwent single lung transplant. Patients were stratified as either mild SPH (mean pulmonary artery pressure 25–40 mm Hg) or severe SPH (mean pulmonary artery pressure >40 mm Hg). Singe lung recipients without PH transplanted over the same time were also examined. Results.: Between January 2017 and December 2019, 318 patients underwent single lung transplantation; 217 had mild SPH (68%), and 59 had severe SPH (18.5%). Forty-two patients without PH underwent single lung transplant. When the groups were compared, significantly higher pulmonary vascular resistance was noted in the severe SPH group, and obesity was noted in both the mild and severe SPH groups. Although the severe SPH group required more intraoperative cardiopulmonary support (37.3% versus 10.3% versus 4.7%, P < 0.05), there were no significant differences in most major postoperative parameters, including the duration of postoperative mechanical ventilation or the incidence of severe primary graft dysfunction. Survival 1 y posttransplant was not significantly different among the groups (93.2% versus 89.4% versus 92.9%, P = 0.58). Conclusions.: Our experience supports the option of single lung transplantation with appropriate intraoperative mechanical circulatory support in patients with SPH. This strategy is worth pursuing, especially with ongoing donor lung shortages.

21 November 2022 in Transplantation
Verified
Journal Article
Closed access
HKHiromu Kehara
Hiromu Kehara
CMChirantan Mangukia
Chirantan Mangukia
GSGengo Sunagawa
Gengo Sunagawa
SISebastian A. Iturra
Sebastian A. Iturra
RYRoh Yanagida
Roh Yanagida
Norihisa ShigemuraNorihisa Shigemura
Norihisa Shigemura
Background.: The role of lung transplantation for coronavirus disease 2019 (COVID-19)–related lung failure is evolving as the pandemic persists. Methods.: From January 2021 to April 2022, 20 patients (median age 62 y; range 31–77) underwent lung transplantation for COVID-related lung failure at our institution. We reviewed their clinical and intraoperative characteristics and early outcomes including postoperative complications. Results.: Eleven patients (55%) had chronic lung disease when they contracted COVID-19. All 20 patients required hospitalization for antivirus treatment. Median lung allocation score was 74.7 (33.1–94.0). Thirteen patients (65%) underwent single-lung transplants, and 7 patients (35%) underwent double-lung transplants. Concomitant coronary artery bypass graft surgery was performed in 2 (10%) patients because of severe coronary artery disease. Postoperatively, venovenous extracorporeal membrane oxygenation was needed in 3 patients (15%) because of severe primary graft dysfunction; all were eventually weaned. Ten patients (50%) experienced deep venous thrombosis, and 1 eventually developed a major pulmonary embolus. The median intensive care unit stay and hospital stays were 6.5 d (3–44) and 18 d (7–77), respectively. During a median follow-up of 201 d (47–418), we experienced 1 late mortality due to COVID-19–related myocarditis. Among the 13 patients with single-lung transplant, 5 demonstrated improvement in their native lungs. Conclusions.: Lung transplantation yielded favorable early outcomes in a heterogeneous patient cohort that included older patients, obese patients, and patients with coronary artery disease or preexisting chronic lung disease. Our data also shed light on the transforming role of lung transplantation for the pulmonary sequelae of a complex multisystem COVID-19 disorder.